Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

Core Insights - Vir Biotechnology, Inc. announced positive results from the Week 48 endpoint analysis of its Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) [1] Group 1: Trial Results - Participants receiving a monthly dose of the combination of tobevibart and elebsiran achieved robust and sustained rates of hepatitis delta virus (HDV) RNA target not detected (TND) [1] - The combination treatment was effective even among participants with cirrhosis and high baseline HDV RNA levels [1]